Rockwell Medical, Inc.
Rockwell Medical, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 1996, the company has established itself as a leader in developing innovative therapies for patients with chronic kidney disease and end-stage renal disease. With a focus on dialysis and iron replacement therapies, Rockwell Medical offers unique products such as Triferic, which is designed to maintain iron levels in patients undergoing dialysis. The company operates primarily in North America, with a growing presence in international markets. Rockwell Medical's commitment to research and development has led to significant milestones, including FDA approvals and partnerships that enhance its market position. Recognised for its dedication to improving patient outcomes, Rockwell Medical continues to advance the field of renal care through its specialised offerings and innovative solutions.
DitchCarbon Score
How does Rockwell Medical, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Rockwell Medical, Inc.'s score of 18 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Rockwell Medical, Inc.'s reported carbon emissions
In 2020, Rockwell Medical, Inc. reported total carbon emissions of approximately 88,100,000 kg CO2e, with emissions distributed across various scopes. The breakdown includes about 20,000,000 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources. Notably, mobile combustion accounted for approximately 11,000,000 kg CO2e, while stationary combustion contributed about 4,000,000 kg CO2e. Scope 2 emissions, primarily from purchased electricity, totalled around 88,100,000 kg CO2e, indicating significant energy consumption. Additionally, Scope 3 emissions, which include indirect emissions from the value chain, amounted to approximately 30,000,000 kg CO2e from purchased goods and services, alongside other categories such as business travel and employee commute. Despite the substantial emissions figures, Rockwell Medical has not publicly disclosed specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of defined climate commitments suggests a need for further engagement in sustainability practices within the industry context. As a company headquartered in the US, Rockwell Medical's emissions data reflects the broader challenges faced by organisations in managing their environmental impact while striving for operational efficiency.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | |
|---|---|
| Scope 1 | 20,000,000 |
| Scope 2 | 88,100,000 |
| Scope 3 | 74,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Rockwell Medical, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
